Madrigal Pharmaceuticals, Inc. $MDGL Stock Position Raised by Peak Financial Advisors LLC

Peak Financial Advisors LLC increased its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 287.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,466 shares of the biopharmaceutical company’s stock after acquiring an additional 3,312 shares during the quarter. Madrigal Pharmaceuticals makes up 1.2% of Peak Financial Advisors LLC’s holdings, making the stock its 21st largest holding. Peak Financial Advisors LLC’s holdings in Madrigal Pharmaceuticals were worth $2,601,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of MDGL. China Universal Asset Management Co. Ltd. boosted its position in shares of Madrigal Pharmaceuticals by 0.7% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 4,459 shares of the biopharmaceutical company’s stock valued at $1,349,000 after purchasing an additional 30 shares during the period. Centaurus Financial Inc. raised its holdings in Madrigal Pharmaceuticals by 5.0% during the 3rd quarter. Centaurus Financial Inc. now owns 709 shares of the biopharmaceutical company’s stock worth $325,000 after buying an additional 34 shares during the period. Orion Porfolio Solutions LLC raised its holdings in Madrigal Pharmaceuticals by 1.3% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 3,638 shares of the biopharmaceutical company’s stock worth $1,101,000 after buying an additional 47 shares during the period. GAMMA Investing LLC lifted its stake in Madrigal Pharmaceuticals by 114.3% during the third quarter. GAMMA Investing LLC now owns 90 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 48 shares in the last quarter. Finally, Global Retirement Partners LLC lifted its stake in Madrigal Pharmaceuticals by 221.7% during the third quarter. Global Retirement Partners LLC now owns 74 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 51 shares in the last quarter. 98.50% of the stock is owned by institutional investors and hedge funds.

Madrigal Pharmaceuticals Price Performance

Shares of MDGL opened at $461.93 on Thursday. The business’s 50-day moving average is $463.40 and its 200-day moving average is $489.10. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.01 and a quick ratio of 3.77. The company has a market capitalization of $10.60 billion, a price-to-earnings ratio of -35.89 and a beta of -0.97. Madrigal Pharmaceuticals, Inc. has a fifty-two week low of $265.00 and a fifty-two week high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) EPS for the quarter, missing the consensus estimate of $0.04 by ($2.61). Madrigal Pharmaceuticals had a negative return on equity of 43.76% and a negative net margin of 30.08%.The company had revenue of $321.08 million for the quarter, compared to analyst estimates of $310.36 million. During the same quarter in the prior year, the business posted ($2.71) earnings per share. The business’s revenue for the quarter was up 210.8% compared to the same quarter last year. Equities research analysts expect that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current fiscal year.

Insider Activity at Madrigal Pharmaceuticals

In other news, General Counsel Shannon T. Kelley sold 360 shares of the business’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $431.94, for a total transaction of $155,498.40. Following the transaction, the general counsel directly owned 12,138 shares in the company, valued at $5,242,887.72. The trade was a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Rebecca Taub sold 491 shares of the company’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $431.94, for a total transaction of $212,082.54. Following the completion of the transaction, the director directly owned 452,213 shares in the company, valued at $195,328,883.22. This trade represents a 0.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 55,612 shares of company stock worth $28,326,065. 21.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on MDGL. The Goldman Sachs Group reissued a “buy” rating and issued a $571.00 target price on shares of Madrigal Pharmaceuticals in a research report on Wednesday, January 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research note on Thursday, January 22nd. Zacks Research upgraded shares of Madrigal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. Citigroup reissued an “outperform” rating on shares of Madrigal Pharmaceuticals in a research note on Tuesday, January 20th. Finally, B. Riley Financial increased their target price on Madrigal Pharmaceuticals from $560.00 to $670.00 and gave the company a “buy” rating in a report on Thursday, December 11th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $685.31.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.